1. The Origins and Mechanism of GLP-1
Discovery and Role in Diabetes Treatment

Diabetes has been known for thousands of years, with the first recorded descriptions dating back to ancient Egypt. The discovery of insulin in the early 20th century revolutionized diabetes treatment, allowing better blood sugar management. However, insulin therapy alone has limitations, particularly its potential to cause hypoglycemia.

In the 1980s, researchers discovered glucagon-like peptide-1 (GLP-1), a hormone secreted by intestinal L cells in response to food intake. Unlike insulin, GLP-1 enhances glucose-dependent insulin secretion, reduces appetite, slows gastric emptying, and suppresses glucagon release, making it a promising target for diabetes treatment.

2. Why is GLP-1 Experiencing a Boom?

Rising Global Demand for Diabetes and Obesity Solutions
The prevalence of diabetes and obesity is skyrocketing worldwide. The increasing incidence of type 2 diabetes, coupled with the global obesity epidemic, has created an urgent need for innovative treatments that address both conditions simultaneously.

GLP-1 receptor agonists (GLP-1RAs) have emerged as game-changing therapies. These drugs not only improve glycemic control but also promote significant weight loss, a major advantage over traditional insulin therapies. This dual benefit has led to explosive growth in the GLP-1 market.

Market Growth and Expansion

The GLP-1 market has seen exponential growth, surpassing $20 billion in 2023. Semaglutide, developed by Novo Nordisk, dominates this sector with its injectable (Ozempic, Wegovy) and oral (Rybelsus) formulations. Future expansion is expected as new indications and delivery methods emerge, further solidifying GLP-1’s market dominance.

3. Hzymes: The Right Timing

Short-Term Challenges

While the GLP-1 market is currently dominated by established pharmaceutical giants, the sector is approaching a pivotal moment. Patents on leading drugs, such as semaglutide, will begin to expire in 2026, opening opportunities for new players to enter the market.

Long-Term Opportunities

Hzymes is strategically positioned to capitalize on this transition. By leveraging biotechnological advancements, particularly in microbial fermentation, Hzymes aims to provide high-quality and cost-effective semaglutide intermediates. This approach ensures a sustainable, scalable supply chain that can support the anticipated market demand surge post-patent expiry.

4. The Market Landscape for Semaglutide

Competitive Landscape

Currently, the market is led by:

• Novo Nordisk (Ozempic, Wegovy, Rybelsus) – market leader
• Eli Lilly (Tirzepatide) – GLP-1/GIP dual agonist
• Emerging Chinese and international pharmaceutical companies investing in semaglutide generics and biosimilars

Market Segmentation

• Regulated Markets (US, EU, China) – High regulatory standards, requiring rigorous clinical trials and approvals
• Non-Patent Markets (Southeast Asia, Latin America, Africa) – Easier entry points, allowing for rapid market penetration

• Alternative Distribution Channels – Pharmacies, online retailers, and medical aesthetic clinics focusing on weight management solutions

5. Customer Segmentation and Targeting

Hzymes categorizes its customers into distinct segments:

• Oral formulation developers – Companies focusing on the next generation of GLP-1 oral drugs
• IND-filing pharmaceutical companies – Firms seeking regulatory approval for semaglutide-based therapies
• Biosimilar peptide manufacturers – Companies exploring biotechnological production methods

• Aesthetic and weight loss clinics – A rapidly growing sector leveraging semaglutide for obesity management

6. Precision Market Penetration – The Upstream and Downstream Supply Chain

Upstream Supply Chain

Hzymes collaborates with key suppliers to secure:

•  Raw materials – Amino acids, conjugation agents, and enzymes
•  Key excipients – SNAC (for oral semaglutide delivery)

•  Manufacturing infrastructure – Injection pens, formulation equipment

Downstream Expansion

• Pharmaceutical companies – IND applicants and generic drug developers
•  Contract manufacturing organizations (CMOs) – Key partners for large-scale production
•  Medical distribution channels – Retail pharmacies, medical aesthetic providers

•  International trade networks – Strategic collaborations in regions without patent restrictions

7. Hzymes’ Product Strategy and Roadmap

Core Product Offering

Hzymes specializes in the fermentation-based production of semaglutide 29-peptide intermediates. This biotechnological approach offers:

•  Cost efficiency – Reducing API production costs
•  Scalability – Enabling rapid expansion to meet market demands

•  Regulatory adaptability – Facilitating approval in diverse global markets

Production Capacity and Expansion Plans

•  Current production: 30 kg/month
•  Planned expansion: 100 kg/month by mid-2025

•  Long-term vision: Regulatory approval for GMP-compliant production

Strategic Focus Areas

•  Short-term – Capturing the non-regulated market with high-quality, cost-effective intermediates
•  Mid-term – Expanding into regulated markets post-2026 patent expiration

•  Long-term – Developing next-generation GLP-1 analogs and biosimilars

Conclusion: Hzymes’ Competitive Edge in the GLP-1 Market

As the GLP-1 market continues its rapid expansion, Hzymes is well-positioned to become a leading supplier of semaglutide intermediates. By leveraging innovative biomanufacturing techniques, targeting key market segments, and strategically expanding its production capacity, Hzymes is poised to play a crucial role in the future of diabetes and obesity treatment.

With the upcoming patent expirations and the increasing demand for cost-effective, high-quality GLP-1 therapies, Hzymes is entering the market at the perfect moment. The company’s commitment to innovation, quality, and scalability ensures a strong foothold in this multi-billion-dollar industry.